Status:

COMPLETED

Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity

Lead Sponsor:

S.LAB (SOLOWAYS)

Collaborating Sponsors:

Center of New Medical Technologies

Triangel Scientific

Conditions:

Overweight and Obesity

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

This clinical trial investigated the combined effects of Semaglutide and a fiber supplement (glucomannan, inulin, psyllium) on weight loss in adults with overweight or obesity. Participants, aged 18-6...

Eligibility Criteria

Inclusion

  • BMI ≥30, or ≥27 with comorbidities.

Exclusion

  • Serious chronic illnesses.
  • History of bulimia or anorexia.
  • Pregnancy or lactation.

Key Trial Info

Start Date :

April 14 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 20 2023

Estimated Enrollment :

81 Patients enrolled

Trial Details

Trial ID

NCT06215196

Start Date

April 14 2023

End Date

August 20 2023

Last Update

January 23 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Center of New Medical Technologies

Novosibirsk, Novosibisk Region, Russia, 630090

Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity | DecenTrialz